

Silent Despair: Unveiling Suicide Risk in People with Dementia

Dr. DEBANJAN BANERJEE¹

¹Department of Psychiatry, APOLLO Multispecialty Hospitals, Kolkata

Key highlights

- Suicide risk is highest in early-stage and younger-onset dementia.
- Dementia subtypes like FTD and DLB show distinct suicide vulnerability profiles.
- Suicide prevention must be integrated into dementia care and policy.

Introduction

Suicide is often perceived as a tragic end to mental illness or existential despair, but rarely is it associated with neurodegenerative conditions like dementia. Yet, mounting evidence indicates that individuals living with dementia are at a heightened—but under-recognized—risk of suicide, particularly in the early stages of the illness. This issue is clinically complex, ethically challenging, and deeply relevant as the global burden of dementia increases.

Commemorating both *World Suicide Prevention Day* (10 September) and *World Alzheimer's Day* (21 September), this article sheds light on an intersection that deserves urgent clinical and public health attention. Suicide prevention in dementia requires a delicate balance between promoting autonomy, recognizing distress, and supporting caregivers. However, the dearth of epidemiological data, especially in low- and middle-income countries, hinders structured approaches. Understanding the scope, risk factors, and avenues for prevention is crucial for clinicians, caregivers, and policy architects alike.

Epidemiology and Risk Overview

Globally, dementia affects over 55 million people, a number projected to double by 2050 [1]. Suicidal ideation and behaviors, though less reported in this population, have been observed with significant clinical consequences. A 2021 meta-analysis found the pooled prevalence of suicidal ideation in individuals with dementia to be around 5%, with higher rates in those newly diagnosed or with comorbid depression [2]. Suicide attempts, although rare, are more frequent during the initial year following diagnosis—suggesting that preserved insight may paradoxically increase risk [3].

Population-based studies in the US and South Korea have reported higher suicide rates among persons with dementia compared to cognitively intact older adults, particularly in younger-onset dementia (before age 65) and in the early stages [4,5]. However, these findings are not consistently replicated across settings, largely due to methodological variations and underreporting—particularly in cultures where suicide is highly stigmatized or legally restricted.

There is an alarming scarcity of reliable data from low-resource countries, where both dementia and suicide are often underdiagnosed. The real burden is likely underestimated. Moreover,

dementia subtype also appears to modulate risk, with certain forms like frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB) linked with higher psychiatric symptom burden, potentially influencing suicidal thoughts or behavior [6].

Mechanisms and Contributing Factors

Several psychological, cognitive, biological, and social factors interact across the illness trajectory to shape risk.

Psychological factors include the experience of hopelessness, anxiety, and reactive depression following diagnosis—especially in individuals with good premorbid functioning or insight. The concept of “existential distress” is particularly pertinent in early dementia, where awareness of declining cognition may provoke fear of dependence or becoming a burden [7]. In some cases, suicidal intent may reflect a perceived loss of autonomy or dignity.

Cognitive factors also play a central role. Unlike severe dementia, where executive dysfunction and apathy often dominate, individuals in the prodromal or mild stages may retain planning abilities, enabling them to contemplate or act on suicidal impulses. This is particularly seen in mild cognitive impairment (MCI) or Alzheimer’s dementia with co-existing depressive symptoms [8].

Biological mechanisms are less understood but likely include dysregulation in serotonergic systems, frontal-subcortical circuitry alterations, and neuroinflammation—common to both depression and neurodegeneration. Studies have found lower serotonergic receptor binding in suicide completers with cognitive impairment, though causality remains unclear [9].

Social and environmental contributors include isolation, caregiver neglect, institutionalization, financial insecurity, and lack of structured engagement. Loneliness, worsened by stigma and inadequate community support, amplifies the risk. Furthermore, in FTD, where disinhibition and impulsivity dominate, suicidal behavior may emerge from altered judgement rather than depressive affect.

Disease-specific risks also merit attention. For instance, individuals with DLB often experience distressing visual hallucinations and delusions, increasing their vulnerability. Similarly, those with FTD may exhibit behavioral impulsivity or loss of empathy, complicating risk recognition [10].

These complex mechanisms highlight the need for tailored assessments that go beyond traditional psychiatric evaluation, incorporating cognitive stage, disease subtype, and environmental context.

Recognizing Warning Signs in People with Dementia

Identifying suicidal risk in people with dementia is fraught with challenges. Communication impairments, cognitive decline, and behavioral disturbances often mask underlying distress. Unlike the general population, where verbalized suicidal ideation may be more straightforward,

individuals with dementia may express such thoughts through behavioral cues—withdrawal, refusal to eat, agitation, or new-onset aggression.

Caregivers and clinicians must be vigilant for non-verbal indicators such as frequent statements about being a burden, sudden calmness after agitation (suggesting decision-making), hoarding medications, or interest in death-themed conversations or media. Co-occurrence of depression, psychosis, or insomnia should heighten concern.

Routine risk assessments—adapted to cognitive level—are essential. Tools such as the Cornell Scale for Depression in Dementia or the Geriatric Suicide Ideation Scale (GSIS) have been used with some success, especially in early-stage dementia or MCI [11]. However, these are rarely used in routine dementia care, leading to missed opportunities for prevention.

Suicide Risk Across Dementia Subtypes and Stages

While most existing literature generalizes dementia as a homogenous entity, clinical experience and emerging data indicate that suicide risk is influenced by the **dementia subtype** and **stage of disease**.

Table 1 summarizes the patterns observed across different dementias.

Table 1. Suicide Risk Patterns in Different Dementia Types and Stages

Dementia Subtype	Stage of Disease	Suicide Risk Profile	Contributing Factors
Alzheimer’s Disease (AD)	Early (MCI/mild)	Moderate ↑	Preserved insight, reactive depression, fear of decline
Alzheimer’s Disease	Moderate-severe	Low ↓	Cognitive incapacity, loss of planning ability
Frontotemporal Dementia (FTD)	All stages	High ↑↑	Disinhibition, impulsivity, poor insight
Dementia with Lewy Bodies (DLB)	Early-moderate	Moderate ↑	Delusions, hallucinations, fluctuating insight
Vascular Dementia	Variable	Variable	Emotional lability, executive dysfunction, comorbid depression
Parkinson’s Disease Dementia (PDD)	Early	Moderate ↑	Hopelessness, apathy, insight preserved initially
Mixed Dementia	Any stage	Moderate ↑	Multifactorial: insight +

			neurobehavioral overlap
--	--	--	-------------------------

(↑ = *increased risk*; ↓ = *decreased risk*)

Prevention Strategies: Clinical and Systemic

Preventing suicide in people living with dementia demands a **multi-tiered approach**, integrating clinical vigilance, psychosocial interventions, and systemic changes.

1 Clinical and Psychosocial Interventions

- **Early psychosocial support post-diagnosis:** The period immediately after diagnosis is a high-risk window. Empathetic disclosure, supportive counselling, and connecting patients with peer groups can reduce distress and isolation [12].
- **Screening and management of depression:** Routine screening for depression, anxiety, and suicidal thoughts using dementia-adapted tools should be part of standard care, especially in memory clinics and primary care settings.
- **Pharmacological considerations:** Antidepressants like SSRIs may be beneficial but require careful monitoring due to polypharmacy. Avoiding medications that exacerbate suicidality (e.g., benzodiazepines in impulsive patients) is critical [13].
- **Modified psychotherapy:** Evidence supports structured psychotherapies such as **Problem Adaptation Therapy (PATH)** and **Dignity Therapy**, which can be tailored to early-stage dementia with good results [14].
- **Caregiver training:** Caregivers are often the first to detect mood changes or behavior shifts. Gatekeeper training and regular psychoeducation should be embedded into dementia care programs [15].

2 System-Level Strategies

- **Integrated care models:** Suicide prevention must be embedded in national dementia plans and community mental health services. Collaboration between neurologists, psychiatrists, general practitioners, and dementia care teams is essential.
- **Institutional protocols:** Residential and long-term care homes should adopt suicide risk monitoring protocols for newly admitted residents with dementia—particularly those with recent hospitalizations or bereavement.
- **Technology and outreach:** Telepsychiatry, helplines, and digital caregiver support systems can reduce isolation and distress, especially in rural or resource-poor settings.
- **Reducing stigma:** Public campaigns must focus on destigmatizing both dementia and mental health, encouraging help-seeking in the elderly.

Box 1: Policy Recommendations for Suicide Prevention in Dementia

- **Mandatory suicide risk screening** in memory clinics and geriatric care settings
- **Inclusion of suicide prevention modules** in dementia caregiver training curricula
- **Standardized post-diagnosis support programs** with mental health input
- **Policy integration** of suicide prevention in national dementia strategies (especially in LMICs)
- **Data collection mandates** for suicide and self-harm in dementia within health information systems
- **Research funding** for culturally adapted interventions in dementia and suicidality
- **Ethical guidance frameworks** on assisted dying in advanced dementia

Global Challenges and Ethical Considerations

Suicide in individuals with dementia raises profound ethical dilemmas that differ from those in the general population. The question of capacity is central—does the person possess the ability to make an informed decision about ending life, or is the desire to die a symptom of a treatable neuropsychiatric condition?

In jurisdictions like Canada, Belgium, and the Netherlands, Medical Assistance in Dying (MAiD) has been extended to include individuals with cognitive impairment under certain conditions, igniting intense debate. While proponents cite autonomy and dignity, critics raise concerns about consent validity, potential coercion, and the slippery slope of euthanasia in vulnerable populations [16].

Cultural beliefs, societal stigma, and religious frameworks also shape how suicide in dementia is perceived and reported. In many low- and middle-income countries (LMICs), suicide remains criminalized, contributing to underreporting and misclassification. Many deaths from overdose, falls, or self-neglect may go undocumented or be attributed to “natural causes” in older adults with dementia.

Research Gaps and Future Directions

There is a clear need for:

- **Prospective cohort studies** evaluating suicidality across dementia types and stages
- **Culturally validated screening tools** tailored for cognitive impairment
- **Intervention trials** assessing psychosocial, pharmacological, and digital strategies
- **Policy implementation research** focusing on real-world suicide prevention integration in dementia care

Additionally, health systems in LMICs must be supported to generate quality data, adapt global models to local needs, and prioritize mental health within geriatric care policy.

Suicide in individuals with dementia is not inevitable—it is **preventable**. Yet, without deliberate clinical vigilance, supportive systems, and research-informed policy, it risks becoming a silent epidemic within the larger dementia crisis.

A nuanced understanding of risk across subtypes and stages, early intervention, and caregiver empowerment are the cornerstones of prevention. As we mark *World Suicide Prevention Day* and *World Alzheimer's Day*, let us advocate for integrated, compassionate, and ethically sound approaches that ensure dignity in both life and death for those living with dementia.

References

1. World Health Organization. Dementia. 2023. Available from: <https://www.who.int/news-room/fact-sheets/detail/dementia>
2. Chin B, Oh KJ, Lee HY. Suicidal ideation in individuals with dementia: a systematic review and meta-analysis. *Int J Geriatr Psychiatry*. 2021;36(10):1534–44.
3. Erlangsen A, Zarit SH, Conwell Y. Suicide among older adults with dementia: a population-based study. *J Am Geriatr Soc*. 2008;56(11):2200–5.
4. Kwon JH, Lee H, Kim HJ. Suicide risk in patients with young-onset dementia: a nationwide cohort study. *J Affect Disord*. 2021;294:704–10.
5. Draper B. Suicidal behaviour and assisted dying in dementia. *Int Psychogeriatr*. 2015;27(10):1613–20.
6. Lapane KL, Dubé CE, Jesdale BM. Clinical correlates and patterns of suicidal ideation in dementia with Lewy bodies and Parkinson's disease dementia. *J Gerontol A Biol Sci Med Sci*. 2020;75(8):1474–80.
7. Braun M, Trujillo M, Di Muro C. Perceived burden and suicidal ideation in Alzheimer's caregivers: a pilot study. *Aging Ment Health*. 2018;22(9):1231–5.
8. Forloni G, Balducci C. Alzheimer's disease, oligomers, and inflammation. *J Alzheimers Dis*. 2018;62(3):1261–76.
9. Underwood MD, Kassir SA, Bakalian MJ, Galfalvy H, Dwork AJ, Mann JJ, Arango V. Serotonin receptors and suicide in Alzheimer's disease. *Brain Res*. 2018;1697:160–9.
10. Mendez MF. The unique predisposition to criminal violations in frontotemporal dementia. *J Am Acad Psychiatry Law*. 2010;38(3):318–23.
11. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. *Biol Psychiatry*. 1988;23(3):271–84.
12. Livingston G, Leavey G, Manela M, Livingston D, Rait G, Sampson EL, et al. Making decisions for people with dementia who lack capacity: qualitative study of family carers in UK. *BMJ*. 2010;341:c4184.
13. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. *J Am Geriatr Soc*. 2011;59(4):577–85.
14. Kiosses DN, Ravdin LD, Gross JJ, Raue PJ, Ioannou M, Banerjee S, et al. Problem Adaptation Therapy for older adults with major depression and cognitive impairment: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(1):22–30.

15. Conwell Y, Van Orden K, Caine ED. Suicide in older adults. *Psychiatr Clin North Am.* 2011;34(2):451–68.
16. van den Berg M, Rietjens JAC, van Thiel GJM. Physician-assisted suicide for patients with dementia in the Netherlands: a qualitative content analysis of Dutch national newspapers. *BMC Med Ethics.* 2019;20(1):22.

Bio sketch



Dr. Debanjan Banerjee is a consultant geriatric psychiatrist at Apollo Multispecialty Hospitals, Kolkata, with clinical and academic interests in dementia care, psychogeriatrics, and public mental health. A Fellow of the Indian Psychiatric Society and trained in sexual medicine, he has contributed to research on late-life mental illness, caregiver support, and ageing policy. He is a global advisor to the ASEM Global Ageing Center, Korea and has served on various advocacy committees, including the International Psychogeriatric Association. Dr. Banerjee is also an active mental health educator, speaker, and writer, working to bridge clinical practice, research, and community awareness.